Avient Launches Biocompatible PEEK Colorants and Pre-Colored Formulations for Healthcare at MEDICA 2024 Part of the Colorant Chromatics™ Transcend™ portfolio, this range of pre-colored formulations and color concentrates are created specifically for the healthcare industry and are especially useful for injection molding and extrusion processes. Targeted for applications such as dental scalers, surgical robots, medical stock and shapes, and portable cardiac monitoring devices, the Colorant Chromatics Transcend Biocompatible PEEK range addresses key industry challenges, such as the need for re-sterilizable and reusable high-temperature polymers that meet biocompatibility standards and maintain good color stability.

Avient Specialty Other Specialty / 2023E(%) 32 79 87 83 81 76 73 90 79 77 76 73 69 60 22 MULTIPLE EXPANSION Avient Specialty Other Specialty / Note: Avient reflects 2023 adjusted EBITDA guidance of $530M and closing share price of $38.51. Further, as a result of Avient's portfolio shift to a pure play specialty formulator, it has completed several acquisitions and divestitures which have resulted in a significant amount of intangible asset amortization. Three Months Ended March 31, 2023 Three Months Ended March 31, 2022 Reconciliation to Condensed Consolidated Statements of Income $ EPS $ EPS Net income from continuing operations attributable to Avient shareholders $ 20.8 $ 0.23 $ 64.4 $ 0.70 Special items, after tax 22.3 0.24 6.4 0.07 Amortization expense, after-tax 15.1 0.16 $ 10.8 $ 0.12 Adjusted net income / EPS $ 58.2 $ 0.63 $ 81.6 $ 0.89 March 31, Reconciliation of Pro Forma Sales 2023 2022 Sales $ 845.7 $ 892.2 APM pro forma adjustments — 94.9 Pro forma sales $ 845.7 $ 987.1 1 Three Months Ended Reconciliation to EBITDA and Adjusted EBITDA: 2023 2022 Net income from continuing operations – GAAP $ 21.3 $ 64.7 Income tax expense 7.7 20.0 Interest expense, net 28.8 16.9 Depreciation and amortization 50.5 37.6 EBITDA from continuing operations $ 108.3 $ 139.2 Special items, before tax 27.3 6.7 Depreciation and amortization included in special items (1.8) (2.1) Adjusted EBITDA $ 133.8 $ 143.8 Pro forma APM adjustments — 32.0 Pro forma adjusted EBITDA $ 133.8 $ 175.8 Pro forma adjusted EBITDA as a % of sales 15.8 % 17.8 % 2023 2022 Sales: Color, Additives and Inks $ 537.0 $ 649.5 Specialty Engineered Materials 309.7 243.1 Corporate (1.0) (0.4) Sales $ 845.7 $ 892.2 Operating income: Color, Additives and Inks $ 65.6 $ 94.5 Specialty Engineered Materials 43.1 38.3 Corporate (51.6) (30.6) Operating income $ 57.1 $ 102.2 Depreciation & amortization: Color, Additives and Inks $ 25.8 $ 26.0 Specialty Engineered Materials 21.2 7.8 Corporate 3.5 3.8 Depreciation & Amortization $ 50.5 $ 37.6 Earnings before interest, taxes, depreciation and amortization (EBITDA): Color, Additives and Inks $ 91.4 $ 120.5 Specialty Engineered Materials 64.3 46.1 Corporate (48.1) (26.8) Other income (expense), net 0.7 (0.6) EBITDA $ 108.3 $ 139.2 AVNT Q1 2023 Earnings Presentation v2 AVNT Q1 2023 Earnings Presentation 5.2 221pm IR Deck - AVNT-2023.03.31 (002).pdf

This defines TPE as a thermoplastic polymer material. This makes LSR a thermoset polymer material.   In Handbook of Polymer Applications in Medicine and Medical Devices,¹ Laurence W.

This defines TPE as a thermoplastic polymer material. This makes LSR a thermoset polymer material.   In Handbook of Polymer Applications in Medicine and Medical Devices,¹ Laurence W.

This defines TPE as a thermoplastic polymer material. This makes LSR a thermoset polymer material.   In Handbook of Polymer Applications in Medicine and Medical Devices,¹ Laurence W.

This defines TPE as a thermoplastic polymer material. This makes LSR a thermoset polymer material.   In Handbook of Polymer Applications in Medicine and Medical Devices,¹ Laurence W.

CUSTOM FORMULATION IMPROVES PRODUCTIVITY AND MANUFACTURING EFFICIENCY CASE STUDY: TRILLIANT™ HC SPECIALTY ENGINEERED MATERIALS Challe nge Accepted. THE IMPACT For the manufacturer, Trilliant™ HC specialty engineered materials provided a number of advantages that contributed to the success of the new product line: • Reduced Cycle Time: The high flow properties of the Trilliant HC formulation allowed the manufacturer to produce warp-free parts that require less packing and cooling time, resulting in a 40% cycle time reduction Through customer intimacy, Avient’s Trilliant HC formulations offered an effective solution that allowed the manufacturer to improve its bottom line and increase its operating income.

Specialty Platform Specialty Platform Specialty Platform

Home // Protecting Polymers from Microbe Growth Subsequent studies then assessed the use of an antimicrobial additive, zinc pyrithione (ZPT), for potential efficacy in a variety of TPE formulations for diverse applications.

Home // Protecting Polymers from Microbe Growth Subsequent studies then assessed the use of an antimicrobial additive, zinc pyrithione (ZPT), for potential efficacy in a variety of TPE formulations for diverse applications.